Doubtful Clinical Benefit of Casirivimab-Imdevimab Treatment for Disease Severity Outcome of High-Risk Patients with SARS-CoV-2 Delta Variant Infection

Noah Shopen, Michal Dekel, Michal Mizrahi, Efrat Zandberg, Nancy Bishouty, Daniel Talmud, Ben Vaknin, Shira Haberman, Malka Katz Shalhav, David Zeltser, Neta Cohen
doi: https://doi.org/10.1101/2022.01.29.22270090

Article Information

doi 
https://doi.org/10.1101/2022.01.29.22270090
History 
  • January 31, 2022.
Copyright 
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.

Author Information

  1. Noah Shopen1,5,*,
  2. Michal Dekel2,5,*,
  3. Michal Mizrahi1,5,
  4. Efrat Zandberg1,5,
  5. Nancy Bishouty4,5,
  6. Daniel Talmud1,5,
  7. Ben Vaknin1,5,
  8. Shira Haberman5,
  9. Malka Katz Shalhav1,5,
  10. David Zeltser1,5 and
  11. Neta Cohen1,3,5,#
  1. 1Emergency Department, Tel Aviv Sourasky Medical Center, Tel Aviv, Israel
  2. 2Division of Infectious Disease, Tel Aviv Sourasky Medical Center, Tel Aviv, Israel
  3. 3Pediatric Emergency Department, Dana Dwek Children Hospital, Tel Aviv Sourasky Medical Center, Tel Aviv, Israel
  4. 4Clinical Pharmacy Unit, Tel Aviv Sourasky Medical Center, Tel Aviv, Israel
  5. 5Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel
  1. ↵#Corresponding author:
    Neta Cohen, MD, Emergency Department, Tel Aviv Sourasky Medical Center, 6 Weizman Street, Tel Aviv, 6423906 Israel. E-mail: netarab81{at}gmail.com.

  1. ↵* Equal contribution

Back to top
Posted January 31, 2022.
Download PDF
Data/Code
Email
Doubtful Clinical Benefit of Casirivimab-Imdevimab Treatment for Disease Severity Outcome of High-Risk Patients with SARS-CoV-2 Delta Variant Infection
Noah Shopen, Michal Dekel, Michal Mizrahi, Efrat Zandberg, Nancy Bishouty, Daniel Talmud, Ben Vaknin, Shira Haberman, Malka Katz Shalhav, David Zeltser, Neta Cohen
medRxiv 2022.01.29.22270090; doi: https://doi.org/10.1101/2022.01.29.22270090
Twitter logo Facebook logo LinkedIn logo Mendeley logo
Citation Tools

Subject Area